IGC Pharma LLC
🇺🇸United States
Clinical Trial on Agitation in Alzheimer's Dementia
Phase 2
Recruiting
- Conditions
- Alzheimer DiseaseAgitation,PsychomotorCare Giving BurdenNPSAggression
- Interventions
- Drug: IGC-AD1-ActiveDrug: IGC-AD1-Placebo
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- IGC Pharma, LLC
- Target Recruit Count
- 164
- Registration Number
- NCT05543681
- Locations
- 🇺🇸
Butler Hospital, Brown University, Providence, Rhode Island, United States
🇨🇦Hamilton Health Sciences , Mcmaster University, Hamilton, Ontario, Canada
🇺🇸ClinCloud, LLC, Melbourne, Florida, United States
Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- IGC Pharma LLC
- Target Recruit Count
- 12
- Registration Number
- NCT04749563
- Locations
- 🇵🇷
Puerto Rico, San Juan, Puerto Rico
© Copyright 2025. All Rights Reserved by MedPath